Hip and pelvic tendinopathies · Review · 2026
Can shockwave help tendon pain around the hip and pelvis?
In this review of 18 reports (927 people), pain generally eased after shockwave for several hip and pelvic tendon problems. In five studies of focused shockwave for outer hip pain, pain scores fell by about 4 points over 12 months. Six studies found better results with shockwave than with the comparison.
Improved over time- reports in the review
- 18
- people, 586 of them treated with shockwave
- 927
- sessions, one a week, in most studies
- 3–4
Good to know: Studies ranged from single-patient reports to trials and were too varied to combine into one number.
Rau OR, Cheng J, Jivanelli B, et al. HSS Journal : the Musculoskeletal Journal of Hospital for Special Surgery, 2026 · Read the paper ↗
How this study worked
What the trials used
- Modality and studies
- Radial ESWT in 11 studies and focused ESWT in 7; no direct focused-versus-radial trial was available in this review.
- Common protocol patterns
- 13/18 studies (72%) used 3–4 weekly sessions; 15/18 (83%) delivered 2,000–3,000 pulses/session. These are review-level counts, not an optimal regimen.
- Focused ESWT settings
- Across the 7 studies using focused ESWT alone: 600–2,500 pulses/session, 1–5 Hz, and 0.03–0.35 mJ/mm²; settings varied by study and diagnosis. The combined protocol in Yun et al. (a radial-ESWT study) added focused ESWT at 1,000 pulses, 0.12–0.5 mJ/mm² and 15 Hz.
- Radial ESWT settings
- Radial protocols typically used 2,000–3,000 pulses at 8–20 Hz and 1.4–4.5 bar; one study used a 500-pulse 1.4-bar minimal-dose comparator. Bar is retained as reported and not converted. These ranges are from the review text; Table 3 prints 1 Hz for Furia and up to 5 bar for Mitchkash (2–5 bar) and Yun (2.5–5.0 bar).
- Co-interventions
- Co-interventions varied; examples included HEP/exercise, physiotherapy, NSAIDs, analgesia, icing advice and activity modification. Individual study contexts are summarized in Tables 1–3.
Who took part
Athletes and other adults with outer hip pain, calcium deposits in hip tendons or hamstring tendon pain; 586 of the 927 people had shockwave.
Side effects
The review counted 65 side effects (an overall rate of 12%), mostly extra pain or skin irritation; with radial shockwave, extra pain usually came on within 24 hours and eased quickly with pain relief. No serious side effects were reported.
All the numbers and the full appraisal
The results, in numbers.
18 reports, 927 participants overall and 586 ESWT-treated; condition counts overlap (GTPS 9 reports, calcific tendinopathy 7, PHT 5).
Multiple pain, function, satisfaction, imaging and return-to-sport measures1 reported outcome
Pain and function across hip/pelvic tendinopathy studies
Multiple pain, function, satisfaction, imaging and return-to-sport measures Narrative synthesis; no pooled effect estimate
The review describes improvement from baseline in pain across studies assessing pain and several favorable study-specific comparisons. It reports a mean 3.9-point pain reduction through 12 months in five focused-ESWT GTPS studies (n=165), not a pooled controlled effect. One study reported no improvement in pain/function after radial ESWT and discontinued due to pain aggravation.
Analysis details and source
No meta-analysis was conducted because protocols, outcomes and timepoints were heterogeneous. Do not treat within-group improvement as a causal ESWT effect or collapse different diagnoses/comparators. The 27-month upper bound is from the Abstract; the Results give follow-up up to 2 years for focused and up to 15 months for radial ESWT. The Abstract's statement that all studies assessing pain showed improvement does not fit the Jo et al. case report, which measured pain and stopped ESWT because pain worsened.
Return-to-sport reporting1 reported outcome
Return to sport in proximal hamstring tendinopathy
Return-to-sport reporting Study-specific narrative and reported proportion
Cacchio et al. reported 80% return to sport by 3 months after radial ESWT in professional athletes. The review does not give the event count in this summary; it is not converted to a count. Case reports describe sports participation or return, but cannot estimate a comparative rate.
Analysis details and source
Table 3 lists n=20 for the Cacchio study, but the 80% narrative is retained as reported rather than converted to an inferred count.
Study-reported adverse events3 reported outcomes
Adverse events reported with focused ESWT
Study-reported adverse events Participants, n/N (%) as reported
Observed subgroup counts; these are not randomized treatment arms.
The review reports 2/175 (1%) with increased or lasting pain requiring medication after focused ESWT; six of 18 reports described adverse events overall.
Analysis details and source
The summary rate is across included studies with variable reporting; nonreporting is not evidence of no events.
Adverse events reported with radial ESWT
Study-reported adverse events Participants, n/N (%) as reported
Observed subgroup counts; these are not randomized treatment arms.
The review reports 63/382 (16%) minor adverse events with radial ESWT, most often skin irritation or increased pain; most increased pain occurred within the 24 hours after treatment and resolved with pain medication. The overall review rate is 65/557 (12%).
Analysis details and source
Rates are descriptive review summaries; the included studies did not use uniform harm surveillance. No between-modality comparison is inferred.
Overall adverse events
Study-reported adverse events Participants, n/N (%) as reported
Observed subgroup counts; these are not randomized treatment arms.
Six of 18 reports described adverse events; the abstract reports 65/557 (12%) overall, mainly increased pain and skin irritation. The authors reported no serious adverse events.
Analysis details and source
The denominator 557 is the review-reported harm denominator and is not the total 927-person review population. Reporting and surveillance varied by study.
Study-specific outcomes reported in the systematic-review narrative and study tables8 reported outcomes
Carlisi 2019, focused ESWT versus ultrasound for GTPS/CT
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
The review reports greater pain improvement with focused ESWT than ultrasound. For LEFS, it reports no improvement, either from baseline or compared with ultrasound, up to 6 months (Table 2: no statistically significant improvement).
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
Heaver 2023, focused ESWT versus corticosteroid injection for GTPS
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
The review reports greater improvement in VAS and HHS at 12 months with focused ESWT than corticosteroid injection, and a greater likelihood of a negative Trendelenburg test after ESWT, for which no timepoint is given; numerical comparative estimates are not supplied here.
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
Notarnicola 2023, focused ESWT versus eccentric exercise for GTPS
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
Outcomes improved from baseline in the ESWT study, but the review reports no differences between eccentric exercise, focused ESWT and crossover groups through reported follow-up.
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
Ramon 2020, focused ESWT versus sham for GTPS
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
The review reports greater improvement versus sham for outcomes at 1, 3 and 6 months, except LEFS at month 1. Roles and Maudsley treatment-satisfaction success was 64.2%; the review summary gives no denominator here.
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
Yagci 2023, radial ESWT versus corticosteroid injection for GTPS
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
The review reports significant improvement in outcome measures at 3 weeks and 3 months and no differences between the radial ESWT and corticosteroid injection groups, without a timepoint for that comparison (Table 3).
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
Rompe 2009, radial ESWT versus home exercise or corticosteroid injection for GTPS
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
The review reports recovery success of 68% at 4 months and 74% at 15 months for the ESWT group; the difference versus home exercise was significant at 4 months but not at 1 or 15 months. No numerical control rates are supplied in the review summary.
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
Wheeler 2022, standard versus minimal-dose radial ESWT for GTPS
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
Both groups improved in pain, function and sleep through 6 months; the review reports no between-group differences. Standard treatment used 2,000 pulses at 2.3–3.3 bar and minimal-dose used 500 pulses at 1.4 bar, three weekly sessions.
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
Yun 2021, radial versus combined ESWT for PHT in runners
Study-specific outcomes reported in the systematic-review narrative and study tables Narrative synthesis; no pooled estimate
VISA-H clinically significant improvement was reported for 63% of the radial group and 57% of the combined group; both groups improved, with no between-group difference reported. These percentages are retained as reported and not converted to counts.
Analysis details and source
This is a study-specific summary, not a pooled or cross-diagnosis estimate. Do not infer missing arm means, denominators, or effect sizes.
How treatment was delivered
Radial ESWT in 11 studies and focused ESWT in 7; no direct focused-versus-radial trial was available in this review.
13/18 studies (72%) used 3–4 weekly sessions; 15/18 (83%) delivered 2,000–3,000 pulses/session. These are review-level counts, not an optimal regimen.
Across the 7 studies using focused ESWT alone: 600–2,500 pulses/session, 1–5 Hz, and 0.03–0.35 mJ/mm²; settings varied by study and diagnosis. The combined protocol in Yun et al. (a radial-ESWT study) added focused ESWT at 1,000 pulses, 0.12–0.5 mJ/mm² and 15 Hz.
Radial protocols typically used 2,000–3,000 pulses at 8–20 Hz and 1.4–4.5 bar; one study used a 500-pulse 1.4-bar minimal-dose comparator. Bar is retained as reported and not converted. These ranges are from the review text; Table 3 prints 1 Hz for Furia and up to 5 bar for Mitchkash (2–5 bar) and Yun (2.5–5.0 bar).
Co-interventions varied; examples included HEP/exercise, physiotherapy, NSAIDs, analgesia, icing advice and activity modification. Individual study contexts are summarized in Tables 1–3.
Six of 18 reports described adverse events. Overall rate 65/557 (12%); focused ESWT 2/175 (1%) with increased/lasting pain requiring analgesics; radial ESWT 63/382 (16%), mainly increased pain or skin irritation. No serious adverse events were reported; incomplete/variable surveillance limits reassurance.
Six of 18 included reports were case reports; evidence quality varied and six studies were judged at higher risk of bias.
No quantitative synthesis was possible because treatment protocols, outcome instruments and follow-up times were heterogeneous; most mixed-diagnosis studies did not separate calcific cases.
No direct focused-versus-radial study was included; only one study used combined ESWT.
Findings checked against the full source by a separate automated reviewer.
Limitations noted by the reviewers
- Six of 18 included reports were case reports; evidence quality varied and six studies were judged at higher risk of bias.
- No quantitative synthesis was possible because treatment protocols, outcome instruments and follow-up times were heterogeneous; most mixed-diagnosis studies did not separate calcific cases.
- No direct focused-versus-radial study was included; only one study used combined ESWT.
Source-linked critical reading
Systematic clinical review
Technical source record
Complete acquired article read: abstract, methods, results, Tables 1–3 and table notes, figure caption, discussion, conclusion and disclosures. Raw HTML contains three tables; parsed extraction did not expose their rows, so raw HTML tables were inspected directly. No linked supplements or primary trial texts were imported.
This review summarizes varied studies suggesting that some people with hip or pelvic tendon conditions improved after shockwave treatment. Because diagnoses, protocols and comparisons differed—and many studies were small or uncontrolled—it cannot show which shockwave method is best or predict an individual result. Temporary pain and skin reactions were reported.
What clinical evidence, shockwave protocols, outcomes, and safety findings have been reported for ESWT in gluteal/hip and pelvic calcific tendinopathy (GTPS/CT) and proximal hamstring tendinopathy (PHT)?
Systematic review searched PubMed/MEDLINE, EMBASE and Cochrane Library through November 1, 2024; 18 clinical reports spanning evidence levels I–V were included. The review combined RCTs, cohort/case-control studies, a quality-improvement study and case reports. It did not pool effects quantitatively.
The 18 reports covered 927 people (682 women, 245 men; mean age 50.7 years); 586 received ESWT. Condition counts overlap: nine reports included GTPS, seven calcific tendinopathy, and five PHT. Five reports concerned active populations (mean age 39.4 years); all PHT participants were athletes in the included studies. The counts by diagnosis sum to more than the number of reports and should not be treated as mutually exclusive.
Eleven studies used radial ESWT and seven used focused ESWT. Across protocols, 13/18 (72%) used three to four weekly sessions and 15/18 (83%) delivered 2,000–3,000 pulses per session. Focused protocols most often reported 2,000 pulses, 4 Hz and 0.10–0.20 mJ/mm², but the full range across the seven focused-only studies was 600–2,500 pulses, 1–5 Hz and 0.03–0.35 mJ/mm². Radial protocols typically used 2,000–3,000 pulses at 8–20 Hz and 1.4–4.5 bar; pressure is not converted to energy flux density. Co-interventions varied by study, including exercise/HEP, physiotherapy, NSAIDs, analgesia and activity advice.
Eight studies had comparison groups, including rest/NSAIDs, physiotherapy, home exercise, eccentric exercise, ultrasound, corticosteroid injection and sham ESWT. Two compared ESWT regimens: standard versus minimal-dose radial ESWT for GTPS and radial versus combined radial-plus-focused ESWT for PHT. The review reports no head-to-head focused-versus-radial trial. Comparisons and co-care differed substantially; no single common comparator applies across diagnoses.
Studies assessed pain (NRS/VAS), function (LEFS, HHS, VISA-H and other instruments), treatment satisfaction/recovery (Roles and Maudsley or Likert), imaging, range of motion, quality of life and return to sport. Follow-up ranged from immediate/0.5 month to 27 months according to the Abstract; the Results give up to 2 years for focused and 15 months for radial ESWT. Across five focused-ESWT GTPS studies, the review reports a mean 3.9-point pain reduction through 12 months (n=165), but provides no pooled estimate or uncertainty interval. Outcomes and timepoints were too heterogeneous for meta-analysis.
The authors report improvement from baseline in pain across studies assessing pain, but those within-group changes do not establish an ESWT effect. Six studies reported a favorable comparison against conservative care, sham, ultrasound or corticosteroid injection; one study found comparable outcomes with eccentric exercise. The review describes no difference between focused ESWT and eccentric exercise in one GTPS trial, between standard and minimal-dose radial ESWT in another GTPS trial, or between radial and combined ESWT in a PHT cohort. For focused ESWT, LEFS findings were mixed: one trial found no improvement or advantage over ultrasound through six months, one found improvement versus baseline but not exercise, and one reported improvement versus sham through six months.
Six of 18 reports described adverse events; the review gives an overall rate of 12% (65/557), mainly increased pain and skin irritation. Its focused-ESWT narrative reports 2/175 (1%) with increased/lasting pain requiring analgesics; radial-ESWT reports 63/382 (16%), most often skin irritation or increased pain; most increased pain arose within 24 hours of treatment and resolved with pain medication. Table 3 includes specific events in some studies, such as bruising, skin irritation, swelling and radiating pain. No serious adverse events were reported, but adverse-event surveillance and reporting were not uniform; nonreporting is not evidence of absence.
The review includes six case reports, and quality varied across the other studies; six studies were judged at higher risk of bias. Protocols and outcome measures differed, preventing quantitative synthesis. Only one study used combined focused and radial ESWT, and no direct focused-versus-radial comparison was available. Most studies mixing calcific tendinopathy with other diagnoses did not report diagnosis-specific outcomes. The search excluded non-English reports.
The evidence combines GTPS, calcific lesions and PHT with different baseline populations, comparators and co-interventions. PHT evidence came from active/athletic populations; it should not be generalized automatically to less active patients. The pooled narrative pain reduction and typical session frequency do not identify an optimal modality, dose or schedule for an individual diagnosis. Most comparative findings are study-specific rather than pooled.
The authors call for standardized ESWT parameters and validated outcome measures. Future diagnosis-specific trials should report co-interventions and harms consistently, distinguish calcific from noncalcific cases, and directly compare focused and radial modalities where clinically appropriate. For GTPS and PHT, trials should clarify whether ESWT adds benefit to exercise or physiotherapy.
Read the original article.
Extracorporeal Shockwave Therapy for Tendinopathies Around the Hip and Pelvis: A Systematic Review.
Rau OR, Cheng J, Jivanelli B, Tenforde AS, Wyss JF. · HSS journal : the musculoskeletal journal of Hospital for Special Surgery · 2026
Open the publication record or available full-text files.
Checked against the full paper · Clinical review: Dr. Marcus Yu Bin Pai, · How we review →